Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438411 · ClinicalTrials.gov registry record · Phase 3
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
A Phase 3 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT01438411 is a Phase 3 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT01438411, a Phase 3 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the therapeutic efficacy and safety of cholic acid in subjects with identified inborn errors of bile acid synthesis.
Interventions
- DRUG Cholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2010-01 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438411
The ClinicalTrials.gov registry entry for NCT01438411 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cholic Acid is the first listed.
NCT01438411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01438411 about?
NCT01438411 is a clinical study titled "Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis". The primary purpose of the study is to evaluate the therapeutic efficacy and safety of cholic acid in subjects with identified inborn errors of bile acid synthesis.
What is the current status of trial NCT01438411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2010-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01438411?
The interventions under investigation include: Cholic Acid (DRUG).
Who is sponsoring clinical trial NCT01438411?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.